Granite Point Capital Management, L.P. Xenon Pharmaceuticals Inc. Transaction History

Granite Point Capital Management, L.P.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$25.44 - $35.16 $508,800 - $703,199	-20,000 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$25.09 - $33.13 $125,450 - $165,650	-5,000 Reduced 20.0%	20,000 $611,000
Q4 2021 Feb 11, 2022	BUY	$15.6 - $35.4 $390,000 - $885,000	25,000 New	25,000 $781,000
Q3 2021 Nov 10, 2021	SELL	$14.86 - $19.45 $1.63 Million - $2.14 Million	-110,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$16.81 - $20.0 $672,400 - $800,000	40,000 Added 57.14%	110,000 $2.05 Million
Q1 2021 May 12, 2021	SELL	$13.65 - $21.31 $946,764 - $1.48 Million	-69,360 Reduced 49.77%	70,000 $1.25 Million
Q4 2020 Feb 05, 2021	SELL	$9.49 - $16.04 $21,827 - $36,892	-2,300 Reduced 1.62%	139,360 $2.14 Million
Q1 2020 May 12, 2020	SELL	$8.08 - $17.57 $1.06 Million - $2.3 Million	-130,883 Reduced 48.02%	141,660 $1.61 Million
Q4 2019 Feb 10, 2020	SELL	$8.11 - $14.65 $194,291 - $350,970	-23,957 Reduced 8.08%	272,543 $3.57 Million
Q3 2019 Oct 30, 2019	SELL	$8.74 - $10.51 $59,432 - $71,468	-6,800 Reduced 2.24%	296,500 $2.67 Million
Q1 2019 May 14, 2019	BUY	$6.39 - $10.42 $319,500 - $521,000	50,000 Added 19.74%	303,300 $3.08 Million
Q4 2018 Feb 05, 2019	SELL	$5.61 - $12.62 $1.18 Million - $2.66 Million	-211,000 Reduced 45.44%	253,300 $1.6 Million
Q3 2018 Nov 13, 2018	SELL	$9.0 - $14.9 $161,100 - $266,710	-17,900 Reduced 3.71%	464,300 $6.13 Million
Q2 2018 Aug 13, 2018	BUY	$4.8 - $9.2 $2.31 Million - $4.44 Million	482,200 New	482,200 $4.44 Million

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.39B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.